Rhumbline Advisers Takes $111,000 Position in NeuroPace, Inc. (NASDAQ:NPCE)

Rhumbline Advisers acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 14,664 shares of the company’s stock, valued at approximately $111,000. Rhumbline Advisers owned about 0.05% of NeuroPace as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of NPCE. Financial Advocates Investment Management increased its position in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after acquiring an additional 5,000 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of NeuroPace in the second quarter valued at about $257,000. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace in the first quarter valued at about $155,000. Acadian Asset Management LLC purchased a new position in shares of NeuroPace in the first quarter worth about $621,000. Finally, Vanguard Group Inc. lifted its holdings in shares of NeuroPace by 18.3% during the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after purchasing an additional 75,512 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

NeuroPace Stock Performance

Shares of NPCE stock opened at $6.97 on Tuesday. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. NeuroPace, Inc. has a 12-month low of $5.75 and a 12-month high of $18.15. The business’s 50 day moving average is $7.31 and its two-hundred day moving average is $9.01. The company has a market capitalization of $200.51 million, a P/E ratio of -5.86 and a beta of 1.80.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The company’s revenue was up 16.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.36) earnings per share. Analysts expect that NeuroPace, Inc. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NPCE shares. Morgan Stanley cut their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th. Wells Fargo & Company reduced their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $18.00 target price on shares of NeuroPace in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.